BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35918330)

  • 1. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
    Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
    Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
    Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
    Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
    Chajuwan T; Kansuwan P; Kobbuaklee S; Chanswangphuwana C
    Leuk Lymphoma; 2022 Feb; 63(2):450-456. PubMed ID: 34585994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
    Zhou Q; Munger ME; Veenstra RG; Weigel BJ; Hirashima M; Munn DH; Murphy WJ; Azuma M; Anderson AC; Kuchroo VK; Blazar BR
    Blood; 2011 Apr; 117(17):4501-10. PubMed ID: 21385853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
    [No Abstract]   [Full Text] [Related]  

  • 7. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
    Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
    Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
    Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
    Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions.
    Wang W; Tan J
    J Oral Pathol Med; 2019 Oct; 48(9):817-825. PubMed ID: 31177574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
    Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.
    Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Zhu L; Zeng H; Schell TD; Zheng H
    Blood Cancer J; 2015 Jul; 5(7):e330. PubMed ID: 26230954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scrutinizing the Expression and Blockade of Inhibitory Molecules Expressed on T Cells from Acute Myeloid Leukemia Patients.
    Abdolmaleki M; Mojtabavi N; Zavvar M; Vaezi M; Noorbakhsh F; Nicknam MH
    Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):265-273. PubMed ID: 29908544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
    Zhou Q; Munger ME; Highfill SL; Tolar J; Weigel BJ; Riddle M; Sharpe AH; Vallera DA; Azuma M; Levine BL; June CH; Murphy WJ; Munn DH; Blazar BR
    Blood; 2010 Oct; 116(14):2484-93. PubMed ID: 20570856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.
    Zhu L; Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Palmisiano ND; Wang M; Jia B; Bayerl M; Schell TD; Hohl RJ; Zeng H; Zheng H
    J Hematol Oncol; 2017 Jun; 10(1):124. PubMed ID: 28629373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
    Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
    Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.